Search

Your search keyword '"Harris, Samuel John"' showing total 15 results
Start Over Author "Harris, Samuel John"
15 results on '"Harris, Samuel John"'

1. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.

Author

Tie, Jeanne, primary, Wang, Yuxuan, additional, Lo, Serigne N, additional, Lahouel, Kamel, additional, Cohen, Joshua D., additional, Wong, Rachel, additional, Shapiro, Jeremy David, additional, Harris, Samuel John, additional, Khattak, Adnan, additional, Burge, Matthew E., additional, Lee, Margaret, additional, Harris, Marion, additional, McLachlan, Sue-Anne, additional, Ananda, Sumitra, additional, UNDERHILL, CRAIG R, additional, Papadopoulos, Nickolas, additional, Tomasetti, Cristian, additional, Kinzler, Kenneth W., additional, Vogelstein, Bert, additional, and Gibbs, Peter, additional

Published
2024
Full Text
View/download PDF

3. Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases

Author

Diamantis, Nikolaos, Harris, Samuel John, Constantinidou, Anastasia, Michalarea, Vasiliki, Fontes, Mariane Sousa, Luken, Maria Jose de Miguel, Avaiya, Tejaskumar Laxmanbhai, Petruckevitch, Ann, Flohr, Donald, Hanwell, Janet, Papadatos-Pastos, Dionysios, Lopez, Juanita, Yap, Timothy Anthony, Bono, Johann S. de, Banerji, Udai, Constantinidou, Anastasia [0000-0001-5316-7574], and Banerji, Udai [0000-0003-1503-3123]

Subjects
Cancer Research, medicine.medical_specialty, Dose limiting toxicity, business.industry, Incidence (epidemiology), Retrospective cohort study, Cancer treatment, Diarrhea, Electronic records, Oncology, Internal medicine, Toxicity, medicine, In patient, medicine.symptom, business
Abstract

2568Background: Diarrhea is a common toxicity related to cancer treatment. Diarrhea occurs at different degrees of severity both within and outside the dose limiting toxicity window, influencing the dose and schedule of novel anticancer drugs. We aimed to assess the incidence, severity and factors predisposing to diarrhea in patients (pts) enrolled in phase I studies. Methods: This is a retrospective study of 1002 separate phase I trial pt-cases treated at the Royal Marsden Hospital Drug Development Unit between January 2010 and December 2014. Data were collected from our electronic records for consecutive pts participating in 80 different phase I trials. Results: The incidence of diarrhea was 32.1%. Grade 1-5 diarrhea was reported in 21.9%, 6.3%, 3.1%, 0.1% and 0.1% pt-cases respectively. 69.5% episodes of diarrhea were reported as drug related. 5.6% of pts had a specific trial intervention due to diarrhea such as dose interruption or withdrawal from study. Time on study was not significantly different i...

Published
2016

4. Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

Author

Chenard-Poirier, Maxime, primary, Kaiser, Martin, additional, Boyd, Kevin, additional, Sriskandarajah, Priya, additional, Constantinidou, Anastasia, additional, Harris, Samuel John, additional, Serrano Fandos, Sonia, additional, Ryan, Alison, additional, Witt, Karolina, additional, Dawes, Joanna C, additional, Parmar, Mona, additional, Turner, Alison Joanne, additional, Tovey, Holly, additional, Hall, Emma, additional, Perez Lopez, Raquel, additional, Tunariu, Nina, additional, Lopez, Juanita Suzanne, additional, De Bono, Johann S., additional, and Banerji, Udai, additional

Published
2017
Full Text
View/download PDF

5. Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience.

Author

Chenard-Poirier, Maxime, primary, Ang, Joo Ern, additional, Harris, Samuel John, additional, Ingles Garces, Alvaro Henrique, additional, Seeramreddi, Satyanarayana, additional, Sundar, Raghav, additional, Collins, Dearbhaile Catherine, additional, Ameratunga, Malaka, additional, Lopez, Juanita Suzanne, additional, De Bono, Johann S., additional, and Banerji, Udai, additional

Published
2017
Full Text
View/download PDF

7. Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases.

Author

Diamantis, Nikolaos, primary, Harris, Samuel John, additional, Constantinidou, Anastasia, additional, Michalarea, Vasiliki, additional, Sousa Fontes, Mariane, additional, de Miguel Luken, Maria Jose, additional, Avaiya, Tejaskumar Laxmanbhai, additional, Petruckevitch, Ann, additional, Flohr, Donald, additional, Hanwell, Janet, additional, Papadatos-Pastos, Dionysios, additional, Lopez, Juanita, additional, Yap, Timothy Anthony, additional, De Bono, Johann S., additional, and Banerji, Udai, additional

Published
2016
Full Text
View/download PDF

8. Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH).

Author

Harris, Samuel John, primary, O'Carrigan, Brent, additional, Lopez, Juanita Suzanne, additional, Bhosle, Jaishree, additional, Banerji, Udai, additional, Popat, Sanjay, additional, De Bono, Johann S., additional, O'Brien, Mary E.R., additional, and Yap, Timothy Anthony, additional

Published
2016
Full Text
View/download PDF

9. Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.

Author

Harris, Samuel John, primary, de Miguel Luken, Maria Jose, additional, Roda Perez, Desamparados, additional, Perez Lopez, Raquel, additional, Parmar, Mona, additional, Prathapan, Vasanthi, additional, Hassam, Hasina, additional, Turner, Alison Joanne, additional, Serrano Fandos, Sonia, additional, Hall, Emma, additional, Tovey, Holly, additional, Tunariu, Nina, additional, Lopez, Juanita Suzanne, additional, Yap, Timothy Anthony, additional, De Bono, Johann S., additional, and Banerji, Udai, additional

Published
2016
Full Text
View/download PDF

12. Awareness, preferences, and experiences of thrombosis and thromboprophylaxis in adults commencing systemic anticancer therapies: TARGET-TP trial.

Author

Alexander, Marliese, Harris, Samuel John, Torres, Javier, Underhill, Craig, Sharma, Sharad, Lee, Nora, Wong, Hui-Li, Eek, Richard Wilhelm, Michael, Michael, Tie, Jeanne, Rogers, Jennifer, Patrick, Rachael, Heriot, Alexander Graham, Ball, David, MacManus, Michael Patrick, Wolfe, Rory, Solomon, Benjamin J., and Burbury, Kate

Published
2023
Full Text
View/download PDF

13. CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.

Author

Lau, Peter Kar Han, Harris, Samuel John, Eastgate, Melissa A., Kee, Damien, Mant, Andrew, Nott, Louise M., Gedye, Craig, Inderjeeth, Andrisha Jade, Underhill, Craig, Weppler, Alison Margaret, Wallace, Roslyn, Lee, Belinda, Au-Yeung, George, Williams, Narelle, Ariza Ospino, Daniel, Gonzales, Louise, Shackleton, Mark J., Lo, Serigne N., McArthur, Grant A., and Sandhu, Shahneen

Published
2023
Full Text
View/download PDF

14. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel (PC) or cisplatin/etoposide (PE) in stage III non-small cell lung cancer (NSCLC).

Author

Liew, Mun Sem, primary, Sia, Joseph, additional, Harris, Samuel John, additional, Tafreshi, Alireza, additional, Starmans, Maud HW, additional, Feigen, Malcolm, additional, Boutros, Paul C, additional, White, Shane, additional, Zimet, Allan Solomon, additional, Lambin, P., additional, Mitchell, Paul, additional, and John, Tom, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results